SCPH
Price
$3.87
Change
-$0.11 (-2.76%)
Updated
Jun 27 closing price
Capitalization
204.3M
38 days until earnings call
THTX
Price
$2.35
Change
+$0.01 (+0.43%)
Updated
Jun 27 closing price
Capitalization
109.98M
Interact to see
Advertisement

SCPH vs THTX

Header iconSCPH vs THTX Comparison
Open Charts SCPH vs THTXBanner chart's image
scPharmaceuticals
Price$3.87
Change-$0.11 (-2.76%)
Volume$688.09K
Capitalization204.3M
Theratechnologies
Price$2.35
Change+$0.01 (+0.43%)
Volume$160.83K
Capitalization109.98M
SCPH vs THTX Comparison Chart in %
Loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCPH vs. THTX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCPH is a Hold and THTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (SCPH: $3.87 vs. THTX: $2.35)
Brand notoriety: SCPH and THTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCPH: 205% vs. THTX: 70%
Market capitalization -- SCPH: $204.3M vs. THTX: $109.98M
SCPH [@Biotechnology] is valued at $204.3M. THTX’s [@Biotechnology] market capitalization is $109.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCPH’s FA Score shows that 0 FA rating(s) are green whileTHTX’s FA Score has 1 green FA rating(s).

  • SCPH’s FA Score: 0 green, 5 red.
  • THTX’s FA Score: 1 green, 4 red.
According to our system of comparison, THTX is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCPH’s TA Score shows that 4 TA indicator(s) are bullish while THTX’s TA Score has 4 bullish TA indicator(s).

  • SCPH’s TA Score: 4 bullish, 5 bearish.
  • THTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both SCPH and THTX are a bad buy in the short-term.

Price Growth

SCPH (@Biotechnology) experienced а +0.78% price change this week, while THTX (@Biotechnology) price change was -7.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

SCPH is expected to report earnings on Aug 06, 2025.

THTX is expected to report earnings on Apr 09, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCPH($204M) has a higher market cap than THTX($110M). THTX YTD gains are higher at: 29.834 vs. SCPH (9.322). THTX has higher annual earnings (EBITDA): 10.1M vs. SCPH (-83.9M). SCPH has more cash in the bank: 57.5M vs. THTX (4.34M). THTX (50.4M) and SCPH (52.4M) have identical debt. THTX has higher revenues than SCPH: THTX (88.7M) vs SCPH (42M).
SCPHTHTXSCPH / THTX
Capitalization204M110M185%
EBITDA-83.9M10.1M-831%
Gain YTD9.32229.83431%
P/E RatioN/AN/A-
Revenue42M88.7M47%
Total Cash57.5M4.34M1,325%
Total Debt52.4M50.4M104%
FUNDAMENTALS RATINGS
SCPH vs THTX: Fundamental Ratings
SCPH
THTX
OUTLOOK RATING
1..100
7163
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4439
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for THTX (100) in the null industry. This means that SCPH’s stock grew somewhat faster than THTX’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as THTX (100) in the null industry. This means that SCPH’s stock grew similarly to THTX’s over the last 12 months.

SCPH's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as THTX (100) in the null industry. This means that SCPH’s stock grew similarly to THTX’s over the last 12 months.

THTX's Price Growth Rating (39) in the null industry is in the same range as SCPH (44) in the Pharmaceuticals Major industry. This means that THTX’s stock grew similarly to SCPH’s over the last 12 months.

THTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that THTX’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCPHTHTX
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRWAX26.230.19
+0.73%
MFS Blended Research Growth Eq A
JSVAX28.660.20
+0.70%
Janus Henderson Contrarian T
JHJCX22.690.15
+0.67%
JHancock ESG Large Cap Core C
TRSPX67.100.35
+0.52%
Nuveen S&P 500 Index Retire
BCEGX21.480.04
+0.18%
Sterling Capital Equity Income C

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-2.76%
CRSP - SCPH
46%
Loosely correlated
N/A
BEAM - SCPH
45%
Loosely correlated
-1.98%
AURA - SCPH
44%
Loosely correlated
-0.16%
YMAB - SCPH
44%
Loosely correlated
-2.08%
AVIR - SCPH
43%
Loosely correlated
-2.27%
More

THTX and

Correlation & Price change

A.I.dvisor tells us that THTX and IDYA have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that THTX and IDYA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To THTX
1D Price
Change %
THTX100%
+0.43%
IDYA - THTX
27%
Poorly correlated
-4.13%
GNPX - THTX
27%
Poorly correlated
-4.70%
SCPH - THTX
26%
Poorly correlated
-2.76%
THRD - THTX
26%
Poorly correlated
-0.37%
CSLLY - THTX
26%
Poorly correlated
-2.96%
More